Review: infliximab increases response and remission rates in fistulizing or treatment-resistant Crohn disease.
نویسنده
چکیده
D a t a s o u r c e s Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, Current
منابع مشابه
Review article: Medical therapy for fistulizing Crohn's disease.
BACKGROUND Fistulae will develop in approximately one-third of patients with Crohn's disease. With an expected spontaneous healing rate of only 10%, fistulizing Crohn's disease requires a comprehensive strategy with a medical and possible surgical approach. AIM To summarize the current literature evaluating various medical options for treating patients with fistulizing Crohn's disease. METH...
متن کاملEfficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
PURPOSE Infliximab is currently used for the treatment of active Crohn's disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. MATERIALS AND METHODS A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were rev...
متن کاملPredictors of response to infliximab in patients with fistulizing Crohn's disease.
OBJECTIVE To evaluate the efficacy and toxicity of infliximab for the treatment of fistulizing Crohn's disease. METHODS Consecutive patients with fistulizing Crohn's disease receiving infliximab were prospectively enrolled. Partial response was defined as a reduction of 50% or more from base-line in the number of draining fistulae. Complete response was defined as the closure of all fistulae....
متن کاملCLINICAL PRACTICE GUIDELINES Infliximab for the treatment of Crohns disease: Review and indications for clinical use in Canada
1Division of Gastroenterology, University of Calgary, Calgary, Alberta Correspondence and reprints: Dr Remo Panaccione, Department of Medicine, University of Calgary, Room 3621 3500 26th Avenue NE, Calgary, Alberta T1Y 6J4. Telephone 403-219-1512, fax 403-291-8017, e-mail [email protected] Received for publication May 2, 2001. Accepted May 2, 2001 R Panaccione, for the Canadian ...
متن کاملA positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
BACKGROUND Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease respond to infliximab treatment. The ability or inability to respond seems to persist over time. Biological characteristics and/or genetic background can influence the response to treatment. The aim was to assess the value of C-reactive protein and TNF-alpha serum levels before treatme...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- ACP journal club
دوره 137 3 شماره
صفحات -
تاریخ انتشار 2002